These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

332 related items for PubMed ID: 22177289

  • 1. Sipuleucel-T (Provenge®) for castration-resistant prostate cancer.
    Di Lorenzo G, Ferro M, Buonerba C.
    BJU Int; 2012 Jul; 110(2 Pt 2):E99-104. PubMed ID: 22177289
    [Abstract] [Full Text] [Related]

  • 2. Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.
    Drugs R D; 2006 Jul; 7(3):197-201. PubMed ID: 16752945
    [Abstract] [Full Text] [Related]

  • 3. Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer.
    Patel PH, Kockler DR.
    Ann Pharmacother; 2008 Jan; 42(1):91-8. PubMed ID: 18094343
    [Abstract] [Full Text] [Related]

  • 4. Sipuleucel-T for prostate cancer: the immunotherapy era has commenced.
    Buonerba C, Ferro M, Di Lorenzo G.
    Expert Rev Anticancer Ther; 2011 Jan; 11(1):25-8. PubMed ID: 21166508
    [Abstract] [Full Text] [Related]

  • 5. Sipuleucel-T (Provenge(®))-Autopsy of an Innovative Paradigm Change in Cancer Treatment: Why a Single-Product Biotech Company Failed to Capitalize on its Breakthrough Invention.
    Jarosławski S, Toumi M.
    BioDrugs; 2015 Oct; 29(5):301-7. PubMed ID: 26403092
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer.
    Shore ND, Mantz CA, Dosoretz DE, Fernandez E, Myslicki FA, McCoy C, Finkelstein SE, Fishman MN.
    Cancer Control; 2013 Jan; 20(1):7-16. PubMed ID: 23302902
    [Abstract] [Full Text] [Related]

  • 8. Clinical Variables Associated With Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Sipuleucel-T Immunotherapy.
    Wei XX, Perry J, Chang E, Zhang L, Hiatt RA, Ryan CJ, Small EJ, Fong L.
    Clin Genitourin Cancer; 2018 Jun; 16(3):184-190.e2. PubMed ID: 29352713
    [Abstract] [Full Text] [Related]

  • 9. Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer.
    Gardner TA, Elzey BD, Hahn NM.
    Hum Vaccin Immunother; 2012 Apr; 8(4):534-9. PubMed ID: 22832254
    [Abstract] [Full Text] [Related]

  • 10. Immunotherapy for metastatic prostate cancer: where are we at with sipuleucel-T?
    Lü C, Williams AK, Chalasani V, Martínez CH, Chin J.
    Expert Opin Biol Ther; 2011 Jan; 11(1):99-108. PubMed ID: 21080858
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Sipuleucel-T: in metastatic castration-resistant prostate cancer.
    Plosker GL.
    Drugs; 2011 Jan 01; 71(1):101-8. PubMed ID: 21175243
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Sipuleucel-T (APC8015) for prostate cancer.
    So-Rosillo R, Small EJ.
    Expert Rev Anticancer Ther; 2006 Sep 01; 6(9):1163-7. PubMed ID: 17020451
    [Abstract] [Full Text] [Related]

  • 18. Sipuleucel-T for the Treatment of Metastatic Hormone-Relapsed Prostate Cancer: A NICE Single Technology Appraisal; An Evidence Review Group Perspective.
    Simpson EL, Davis S, Thokala P, Breeze PR, Bryden P, Wong R.
    Pharmacoeconomics; 2015 Nov 01; 33(11):1187-94. PubMed ID: 26017401
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.